Medtronic Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Medtronic wird ein jährliches Gewinn- und Umsatzwachstum von 12.9% bzw. 4.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.4% betragen.

Wichtige Informationen

12.9%

Wachstumsrate der Gewinne

13.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.7%
Wachstumsrate der Einnahmen	4.3%
Zukünftige Eigenkapitalrendite	15.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:MDTC34 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
4/30/2027	36,729	5,997	6,778	9,000	18
4/30/2026	35,024	5,709	6,771	8,637	31
4/30/2025	33,416	5,006	6,540	8,009	30
4/26/2024	32,364	3,676	5,200	6,787	N/A
1/26/2024	32,320	4,201	4,931	6,470	N/A
10/27/2023	31,958	4,102	4,045	5,570	N/A
7/28/2023	31,558	3,620	4,444	5,831	N/A
4/28/2023	31,227	3,758	4,580	6,039	N/A
1/27/2023	30,771	4,064	4,166	5,636	N/A
10/28/2022	30,806	4,321	4,822	6,290	N/A
7/29/2022	31,070	5,205	5,721	7,137	N/A
4/29/2022	31,686	5,039	5,978	7,346	N/A
1/28/2022	31,785	4,914	5,678	7,034	N/A
10/29/2021	31,798	4,704	5,773	7,162	N/A
7/30/2021	31,597	3,882	5,855	7,254	N/A
4/30/2021	30,117	3,606	4,885	6,240	N/A
1/29/2021	27,926	2,892	4,631	5,945	N/A
10/30/2020	27,868	3,537	4,752	5,996	N/A
7/31/2020	27,927	4,412	4,756	6,002	N/A
4/24/2020	28,913	4,789	6,021	7,234	N/A
1/24/2020	31,062	5,408	6,659	7,871	N/A
10/25/2019	30,891	4,762	6,298	7,519	N/A
7/26/2019	30,666	4,420	5,671	6,815	N/A
4/26/2019	30,557	4,631	5,873	7,007	N/A
1/25/2019	30,555	4,826	4,867	5,958	N/A
10/26/2018	30,378	2,168	4,864	5,905	N/A
7/27/2018	29,947	3,163	4,568	5,649	N/A
4/27/2018	29,953	3,104	3,616	4,684	N/A
1/26/2018	29,725	2,859	N/A	5,419	N/A
10/27/2017	29,639	5,069	N/A	5,502	N/A
7/28/2017	29,934	4,115	N/A	6,067	N/A
4/28/2017	29,710	4,028	N/A	6,880	N/A
1/27/2017	29,361	3,968	N/A	6,433	N/A
10/28/2016	29,012	4,242	N/A	6,145	N/A
7/29/2016	28,725	3,647	N/A	5,952	N/A
4/29/2016	28,833	3,538	N/A	5,218	N/A
1/29/2016	28,435	2,434	N/A	5,804	N/A
10/30/2015	25,819	2,316	N/A	5,774	N/A
7/31/2015	23,127	2,624	N/A	5,408	N/A
4/24/2015	20,261	2,675	N/A	4,902	N/A
1/23/2015	17,410	3,124	N/A	4,318	N/A
10/24/2014	17,255	2,909	N/A	4,163	N/A
7/25/2014	17,083	2,983	N/A	4,286	N/A
4/25/2014	16,893	3,065	N/A	4,959	N/A
1/24/2014	16,879	3,586	N/A	4,901	N/A
10/25/2013	16,743	3,812	N/A	4,735	N/A
7/26/2013	16,644	3,556	N/A	4,593	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MDTC34Das prognostizierte Gewinnwachstum (12.9% pro Jahr) liegt über der Sparquote (9.9%).

Ertrag vs. Markt: MDTC34Die Erträge des Unternehmens (12.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt BR (14% pro Jahr).

Hohe Wachstumserträge: MDTC34Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: MDTC34Die Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt BR (7.1% pro Jahr).

Hohe Wachstumseinnahmen: MDTC34Die Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MDTC34Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.4%).

Medtronic Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Provides Revenue Results for the Second Half of 2023

Medtronic plc Reiterates Earnings Guidance for the Year 2023

Recent updates

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Medtronic plc to Report Q3, 2024 Results on Feb 20, 2024

Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Medtronic Announces First Patient Enrolled in U.S. Clinical Trial for Hugo™ Robotic-Assisted Surgery System

Medtronic plc Approves Cash Dividend for the Third Quarter of Fiscal Year 2023, Payable on January 13, 2023

Medtronic Completes Enrollment in Pivotal Trial Evaluating First-Of-Its-Kind Pulsed Field Ablation Catheter for Patients with Atrial Fibrillation

Medtronic plc Provides Revenue Results for the Second Half of 2023

Medtronic's SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with Other SPYRAL HTN Renal Denervation Trials

Medtronic plc Launches of Medtronic Neurovascular Co-Lab Platform to Accelerate Innovation in Stroke Treatment

dorsaVi Partners with Medtronic to Develop New Technology

Medtronic plc Introduces New Program Called My Insights Exclusively Made for Individuals Using MiniMed™ 770G System

Medtronic plc to Receive FDA Approval for Pacing the Heart's Natural Conduction System

Medtronic plc Receives FDA Clearance for Expanded Indication of LINQ II™ Insertable Cardiac Monitor for Use in Pediatric Patients Ages 2 and Older

Medtronic plc Announces SYMPLICITY HTN-3 Trial Data Show Sustained Long-Term Blood Pressure Reductions with Medtronic Renal Denervation Procedure

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Medtronic plc

Medtronic plc Adapt Study Results Published in the Lancet Diabetes & Endocrinology Show Improved Glycemic Control and Treatment Satisfaction Among Those Using Minimed™ 780G System¹, Compared to Insulin Injections

Medtronic plc (NYSE:MDT) completed the acquisition of remaining 97% stake in Affera, Inc.

Medtronic plc Reiterates Earnings Guidance for the Year 2023

Medtronic plc, Annual General Meeting, Dec 08, 2022

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2023, Payable on October 14, 2022

Medtronic plc Receives FDA Clearance for Next-Generation UNiD Spine Analyzer with Degenerative Spine Surgery Predictive Model

Medtronic plc (NYSE:MDT) completed the acquisition of Left-heart Access Portfolio from Acutus Medical, Inc. (NasdaqGS:AFIB).

Medtronic plc Appoints Lidia Fonseca as an Independent Director

Medtronic plc(NYSE:MDT) dropped from Russell Top 50 Index

Medtronic plc Approves Increase in Ash Dividend for the First Quarter of Fiscal Year 2023, Payable on July 15, 2022

Medtronic Receives FDA Approval for Latest Generation Drug-Eluting Coronary Stent System

Medtronic plc Announces Executive Changes

Medtronic plc Announces Cash Dividend for Fourth Quarter of Fiscal Year 2022, Payable on April 22, 2022

Medtronic plc Announces Launch of Nuvent™ Eustachian Tube Dilation Balloon

Medtronic plc Receives FDA Approval for InterStim X™ System, the Next Generation of the Most Personalized Sacral Nerve Stimulation Therapy for Bladder and Bowel Control

Medtronic plc Receives FDA Expanded Approval for Cardiac Cryoablation Catheters for Pediatric Treatment of a Common Heart Rhythm Condition

Medtronic plc to Report Q4, 2023 Results on May 25, 2023

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken